Availability of comparative efficacy data at the time of drug approval in the United States.
about
Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic reviewAdoption of ipilimumab in the United States: a Medicare study.Learning from hackers: open-source clinical trials.Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.A pragmatic view on pragmatic trials.Comparative effectiveness of inhaled corticosteroids for paediatric asthma: protocol for a systematic review and Bayesian network meta-analysis.Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillationClinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014.Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development.Patterns and predictors of physician adoption of new cardiovascular drugs.A Bias in the Evaluation of Bias Comparing Randomized Trials with Nonexperimental Studies.Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.Comparator bias: why comparisons must address genuine uncertainties.The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs
P2860
Q26781716-26D489B4-677E-4967-AE8E-6A451484FC49Q30276953-C47D4BCF-0FFC-4168-9C8B-C053D7D7A72EQ33761499-9A803B5B-C413-41D2-86AE-53F3B7E6AA35Q34089761-FFC01E1A-3F3C-4951-BBDB-D2135A2483DFQ35089550-2F2A0B29-8E54-486A-816B-2DCE0235EDDDQ35237327-68F5C32E-0782-4212-879D-F890BAC728E4Q36205132-FE5C930D-A473-479F-8336-1293E4780DBFQ36317589-6F0A2C50-A099-41B7-827A-3D9D7FCEFDE6Q39002683-CC5845B7-FDFF-475B-9856-B8846D4EB378Q43430988-04ADFD7A-3CD1-4B07-BCF0-3AE8927D7B7EQ46590970-55525338-EDA4-44B0-8CED-ABC506DC4E13Q47369874-0D0DA4EB-6041-40AA-AC5B-BF9C20F7E101Q50001044-E54CEE32-34CD-4C1E-AB1A-7468F3198FFEQ53113470-B82CB5B3-1742-42A5-AC39-B1CC9E431DE3Q58718992-30258437-68BF-4982-A222-4EA18FCC4080
P2860
Availability of comparative efficacy data at the time of drug approval in the United States.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Availability of comparative ef ...... approval in the United States.
@ast
Availability of comparative ef ...... approval in the United States.
@en
type
label
Availability of comparative ef ...... approval in the United States.
@ast
Availability of comparative ef ...... approval in the United States.
@en
prefLabel
Availability of comparative ef ...... approval in the United States.
@ast
Availability of comparative ef ...... approval in the United States.
@en
P2093
P356
P1476
Availability of comparative ef ...... approval in the United States.
@en
P2093
Joshua J Gagne
Mary K Kowal
Nikolas H Goldberg
Sebastian Schneeweiss
P304
P356
10.1001/JAMA.2011.539
P407
P577
2011-05-01T00:00:00Z